Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.
The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.In this non-infer...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5766122?pdf=render |
id |
doaj-40052717e93546ff808207c26154cf36 |
---|---|
record_format |
Article |
spelling |
doaj-40052717e93546ff808207c26154cf362020-11-25T01:24:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01131e019058110.1371/journal.pone.0190581Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.Heon Ju LeeSang Jin KimYoung Oh KweonSoo Young ParkJeong HeoHyun Young WooJae Seok HwangWoo Jin ChungChang Hyeong LeeByung Seok KimJeong Ill SuhWon Young TakByoung Kuk JangThe efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.In this non-inferiority trial, patients with LAM-resistant CHB and undetectable serum HBV DNA (<20 IU/mL) for >6 months after initiating LAM+ADV combination therapy were randomized (1:2) either to continue the combination therapy (LAM+ADV group, n = 58) or switched to TDF monotherapy (TDF group, n = 111). They were followed-up with serum biochemistry tests and HBV DNA measurement at 12-week intervals for 96 weeks. The primary endpoint of this study was the proportion of patients with viral reactivation at week 96.Patients with CHB enrolled in this study (n = 169) included 74 patients with compensated liver cirrhosis. In total, 9 patients (4 in the LAM+ADV group and 5 in the TDF group) dropped-out from the study. After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%). None of the subjects in either group experienced viral reactivation based on per protocol analysis. No serious adverse reactions were observed. In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA. However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.ClinicalTrials.gov NCT01732367.http://europepmc.org/articles/PMC5766122?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Heon Ju Lee Sang Jin Kim Young Oh Kweon Soo Young Park Jeong Heo Hyun Young Woo Jae Seok Hwang Woo Jin Chung Chang Hyeong Lee Byung Seok Kim Jeong Ill Suh Won Young Tak Byoung Kuk Jang |
spellingShingle |
Heon Ju Lee Sang Jin Kim Young Oh Kweon Soo Young Park Jeong Heo Hyun Young Woo Jae Seok Hwang Woo Jin Chung Chang Hyeong Lee Byung Seok Kim Jeong Ill Suh Won Young Tak Byoung Kuk Jang Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. PLoS ONE |
author_facet |
Heon Ju Lee Sang Jin Kim Young Oh Kweon Soo Young Park Jeong Heo Hyun Young Woo Jae Seok Hwang Woo Jin Chung Chang Hyeong Lee Byung Seok Kim Jeong Ill Suh Won Young Tak Byoung Kuk Jang |
author_sort |
Heon Ju Lee |
title |
Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. |
title_short |
Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. |
title_full |
Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. |
title_fullStr |
Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. |
title_full_unstemmed |
Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. |
title_sort |
evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis b patients. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.In this non-inferiority trial, patients with LAM-resistant CHB and undetectable serum HBV DNA (<20 IU/mL) for >6 months after initiating LAM+ADV combination therapy were randomized (1:2) either to continue the combination therapy (LAM+ADV group, n = 58) or switched to TDF monotherapy (TDF group, n = 111). They were followed-up with serum biochemistry tests and HBV DNA measurement at 12-week intervals for 96 weeks. The primary endpoint of this study was the proportion of patients with viral reactivation at week 96.Patients with CHB enrolled in this study (n = 169) included 74 patients with compensated liver cirrhosis. In total, 9 patients (4 in the LAM+ADV group and 5 in the TDF group) dropped-out from the study. After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%). None of the subjects in either group experienced viral reactivation based on per protocol analysis. No serious adverse reactions were observed. In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA. However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.ClinicalTrials.gov NCT01732367. |
url |
http://europepmc.org/articles/PMC5766122?pdf=render |
work_keys_str_mv |
AT heonjulee evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients AT sangjinkim evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients AT youngohkweon evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients AT sooyoungpark evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients AT jeongheo evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients AT hyunyoungwoo evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients AT jaeseokhwang evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients AT woojinchung evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients AT changhyeonglee evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients AT byungseokkim evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients AT jeongillsuh evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients AT wonyoungtak evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients AT byoungkukjang evaluatingtheefficacyofswitchingfromlamivudineplusadefovirtotenofovirdisoproxilfumaratemonotherapyinlamivudineresistantstablehepatitisbpatients |
_version_ |
1725119265668857856 |